Potential metabolic interaction between St John's wort and theophylline

被引：141

作者：

Nebel, A ^{[1
]}

Schneider, BJ

Baker, RK

Kroll, DJ

机构：

[1] Physician Hlth Partners, Managed Care Pharm Serv, Denver, CO USA

[2] Xenometrix Inc, Client Res, Boulder, CO USA

[3] Univ Colorado, Hlth Sci Ctr, Sch Pharm,Mol Toxicol & Environm Hlth Sci Program, Dept Pharmaceut Sci, Denver, CO 80262 USA

来源：

ANNALS OF PHARMACOTHERAPY | 1999年 / 33卷 / 04期

关键词：

D O I：

10.1345/aph.18252

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：502 / 502

页数：1

共 5 条

[1] Apparent decrease in population clearance of theophylline: Implications for dosage [J].

Asmus, MJ ;

Weinberger, MM ;

Milavetz, G ;

Marshik, P ;

Teresi, ME ;

Hendeles, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (05) :483-489

[2] ROLE OF CYTOCHROME P4501A2 IN CHEMICAL CARCINOGENESIS - IMPLICATIONS FOR HUMAN VARIABILITY IN EXPRESSION AND ENZYME-ACTIVITY [J].

EATON, DL ;

GALLAGHER, EP ;

BAMMLER, TK ;

KUNZE, KL .

PHARMACOGENETICS, 1995, 5 (05) :259-274

[3] Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin [J].

Kerb, R ;

Brockmoller, J ;

Staffeldt, B ;

Ploch, M ;

Roots, I .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2087-2093

[4] PHARMACOKINETIC INTERACTIONS BETWEEN THEOPHYLLINE AND OTHER MEDICATION .1. [J].

UPTON, RA .

CLINICAL PHARMACOKINETICS, 1991, 20 (01) :66-80

[5]

Vandenbogaerde AL, 1996, ANTICANCER RES, V16, P1619

← 1 →